ASCR under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year 31, March 2026
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Marksans Pharma Ltd has filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required under SEBI Regulation 24A. The report was issued by Jinesh Dedhia & Associates, Practicing Company Secretaries. The secretarial auditor examined compliance with SEBI regulations including LODR 2015, ICDR, SAST 2011, SBEB Regulations, and PIT Regulations. All 13 compliance checkpoints reviewed showed 'Yes' status, including secretarial standards, board processes, website disclosures, director qualifications, related party transactions, and insider trading norms. No actions were taken by SEBI or stock exchanges against the company during the review period. No non-compliances were observed.
Clean compliance report with no regulatory observations or penalties is positive for shareholders, indicating strong corporate governance and adherence to SEBI norms, which supports investor confidence.